The consumer health company also disclosed its CEO’s departure, following its CFO replacement earlier this year, and appointed an interim chief executive. Preliminary second-quarter 2025 results show ...

After years of post-COVID-19 normalization and the impact of its Kenvue spinoff, Johnson & Johnson’s (NYSE: JNJ) stock price ...

Aid, Listerine, Neutrogena, and Johnson's consumer products, reported disappointing Q2 sales and just announced that its CEO ...

The 12-month price targets, analyzed by analysts, offer insights with an average target of $23.58, a high estimate of $25.00, ...

Kenvue’s board of directors are considering ‘a broad range of potential alternatives’ and are hunting for a permanent ...

Kenvue says that CEO Thibaut Mongon is departing as the maker of Listerine and Band-Aid brands continues with a strategic ...

Kenvue (KUVE) has named Kirk Perry, a current director, as its interim CEO, effective immediately. Concurrently, Thibaut ...

Kenvue Inc. (NYSE:KVUE) is one of the 12 best consumer goods stocks billionaires are quietly buying. On June 24, the company ...

Shares of Kenvue rose in early Thursday trading after the maker of Band-Aid, Tylenol, and Listerine reported first-quarter results better than analysts' estimates.

Kenvue KVUE 2.01%, the Johnson & Johnson spinoff that makes Tylenol and Benadryl, logged earnings growth ahead of expectations, named a new chief financial officer and boosted its sales-growth ...

Kenvue’s Q2 earnings, revenue beat expectationsFor the full year 2025, Kenvue now expects net sales growth of 1% to 3% year-over-year, including organic sales growth of 2% to 4% and a roughly 1% ...

On a per-share basis, the Skillman, New Jersey-based company said it had net income of 17 cents. Earnings, adjusted for one-time gains and costs, were 24 cents per share.